Letters
Industry payments and low value cancer drugs
Use of denosumab in castration sensitive prostate cancer
BMJ 2023; 383 doi: https://doi.org/10.1136/bmj.p2827 (Published 04 December 2023) Cite this as: BMJ 2023;383:p2827
- Michaël R Laurent, consultant geriatrician
- Imelda Hospital, Bonheiden, Belgium
- michael.laurent{at}imelda.be
In their article, Mitchell and colleagues state that the use of denosumab in men with castration sensitive metastatic prostate cancer who lack an appropriate indication (such as osteoporosis) constitutes non-recommended, low value care.1
Standard treatment for this group of patients, however, is androgen deprivation therapy, which inherently carries an increased risk …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.